Cancer Research and Treatment

The Effect of Pentoxifylline on Radiobiological Parameters in the Rat Radiation Myelopathy: Won Dong Kim, Woo Yoon Park; Cancer Res Treat. 2006;38(4):229-233. Published online December 31, 2006; DOI: https://doi.org/10.4143/crt.2006.38.4.229

Abstract PDF PubReader ePub: Purpose
There is great recent interest in the potential value of using pentoxifylline (3,7-dimethyl-1(5-oxyhexyl)-xanthine, PTX) as an inhibitor of radiation-induced late normal tissue damage. The effects of PTX on the radiobiological parameters (α/β ratio, repair half time T_1/2) of radiation myelopathy were studied in a rat model.
Materials and Methods
Anesthetized Sprague-Dawley rats received irradiation to 2 cm of their cervical spines with using a 6MV LINAC (dose rate: 3 Gy/min). Radiation was administered in single, two, four and eight fractions with a fraction interval of 24 h with or without PTX. PTX was added to the rats' distilled drinking water at a concentration of 2 g/L; the water was consumed ad libitum. After tabulation of the ED₅₀ (the estimated dose needed to produce 50% paralysis in a group of irradiated animals), α/β could be estimated from the ratio of the slope to the intercept of the reciprocal-dose plot. Subsequently, the repair half time T_1/2 was obtained from the data of the experimental group that received a pair of 7 Gy fractions on each day, separated by intervals of 4 and 8 h.
Results
The α values calculated for RT alone and RT+ PTX were almost the same. We noticed that the β value for the RT+PTX was lower than that for RT alone. So, the α/β ratio for the RT+PTX was higher. The T_1/2 obtained from monoexponential model was 3.27 and 2.58 h for RT alone and RT+PTX, respectively.
Conclusion
PTX increased the α/β ratio and it decreased the T_1/2 of radiation myelopathy, suggesting that a decreasing fractionation sensitivity occurred. This implies that PTX, which distinctly acts upon the bending region of the high dose, may be expected to protect the spinal cord with a larger fraction size.

7,533 View
40 Download

Concurrent FP (5-fluorouracil, cisplatin) Chemoradiotherapy for Patients with Esophageal Cancer: Min Ok Kim, Eui Sil Hong, Ji Young Chai, Joung Muk Leem, Il Young You, Won Dong Kim, Woo Yoon Park, Seung Taik Kim, Ki Hyeong Lee; Cancer Res Treat. 2003;35(4):330-334. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.330

PURPOSE
The outcomes of a surgical approach for patients with an esophageal carcinoma remain unsatisfactory despite its high complication rates. We conducted a phase II trial, using combined FP (5-fluorouracil and cisplatin) chemotherapy and concurrent radiotherapy, as a definitive therapy for patients with esophageal cancer.
MATERIALS AND METHODS
Patients with histologically proven esophageal cancer were enrolled onto this study. The treatment consisted of four courses of chemotherapy and six and a half weeks of radiotherapy. The patients received chemotherapy in weeks 1, 5, 12 and 16 (5-fluorouracil 1, 000 mg/m2 on days 1 to 4 and cisplatin 75 mg/m2 on day 1). Radiotherapy was administered at a dose of 59.4 Gy, in five 1.8 Gy fractions a week.
RESULTS
A total of 22 eligible patients entered the study. Of the 19 evaluable patients, a complete response occurred in 7 (37%), and a partial response in 8 (42%). After a median follow-up of 35 months, the overall survival rate was 32% at three years and the median survival was 11 months. Fourteen (64%) received planned dose of radio-therapy and 13 (59%) received more than three courses of chemotherapy. However, there was no difference in three-year survival rates between the patients that received less than three courses of chemotherapy and those that received three or more courses (31% vs. 32%). The major treatment related toxicity was mucositis, which developed in every patient, with grades III or IV in thirteen (59%) patients. During the treatment, the patients lost, on average, 3.8% of their body weight. The mean hospital stay was 23 days, with a total duration of treatment of 74 days.
CONCLUSIONS
Concurrent FP chemoradiotherapy was effective as a definitive therapy for patients with esophageal cancer. The major toxicity was mucositis. Although the treatment was relatively feasible, a randomized trial of reduced courses of chemotherapy is warranted.

Citations

Citations to this article as recorded by

Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE₂
Ivan Ho Yuen Pun, Dessy Chan, Sau Hing Chan, Po Yee Chung, Yuan Yuan Zhou, Simon Law, Alfred King Yin Lam, Chung Hin Chui, Albert Sun Chi Chan, Kim Hung Lam, Johnny Cheuk On Tang
Cancer Research and Treatment.2017; 49(1): 219. CrossRef
Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
Sang-Hee Cho, Ik-Joo Chung, Sang-Yun Song, Deok-Hwan Yang, Jeong-Rae Byun, Yeo-Kyeoung Kim, Je-Jung Lee, Kook-Joo Na, Hyeoung-Joon Kim
Journal of Korean Medical Science.2005; 20(4): 618. CrossRef

4,842 View
30 Download
2 Crossref

Concurrent Etoposide/Cisplatin Combination Chemotherapy (EP) and Thoracic Radiotherapy after Two Cycles of EP for Limited Stage Small Cell Lung Cancer: Hee Jung Sohn, Sang We Kim, Jin Hee Ahn, Hye Jin Kang, Sarah Park, Heon Nyoung Jung, Cheol Won Suh, Woo Kun Kim, Sang Wook Lee, Eun Kyung Choi, Sang Do Lee, Woo Sung Kim, Dong Sun Kim, Won Dong Kim, Jung Shin Lee; Cancer Res Treat. 2002;34(6):409-415. Published online December 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.6.409

Abstract PDF

Purpose
s: Although the standard management of limited stage small cell lung cancer is concurrent platinum-based chemotherapy with thoracic radiotherapy (TRT), the optimal timing of the TRT remains controversial. We investigated the feasibility of concurrent chemoradiation for the patients with limited stage small cell lung cancer after 2 cycles of combination chemotherapy with Etoposide/Cisplatin (EP).
MATERIALS AND METHODS
EP consisted of Etoposide 100 mg/m2 on day 1 to 3 and Cisplatin 70 mg/m2 on day 1. Six cycles were given to the responders every 4 weeks. Total 55 Gy (1.8 Gy once-daily or 1.2 Gy twice-daily, 5 days per week) of TRT were given to the patients who showed at least a partial response after 2 cycles of EP. The other patients were treated by the physician's decision. The patients with complete remission were recommended to receive prophylactic cranial irradiation.
RESULTS
Fifty patients were enrolled. Thirty-five (70%) of them showed responses (2 complete remissions and 33 partial remissions) after 2 cycles of EP. Thirty-three of the responders were given TRT starting with the 3rd cycle of EP. The nonresponders were treated with salvage chemotherapy and TRT. After completion of treatment for 50 patients, the overall response rate was 86% (29 complete remissions, 14 partial remissions). One patient (2%) showed stable disease, and 6 (12%) showed a progressive disease. The median progression free survival was 326 days and the median survival time was 410 days. One-, 2-, 3-, 4- and 5-year survival rates were 62%, 24%, 14%, 9% and 6%, respectively. As hematologic toxicities during chemoradiation, 35.1% with grade III/IV neutropenia and 18.9% with grade III/IV thrombocytopenia were noted. Grade II/III radiation pneumonitis and radiation esophagitis were noted in 5/1 and 13/1 patients (15.2%/ 3.0% and 39.4%/3.0%), respectively. One patient died of septicemia during chemoradiation.
CONCLUSION
The concurrent EP and TRT after 2 cycles of EP was feasible in limited stage small cell lung cancer. Further study is required for the indentification of optimum timing of TRT during combination chemotherapy.

Citations

Citations to this article as recorded by

Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer
In-Bong Ha, Bae-Kwon Jeong, Hojin Jeong, Hoon-Sik Choi, Gyu-Young Chai, Myoung-Hee Kang, Hoon Gu Kim, Gyeong-Won Lee, Jae-Beom Na, Ki-Mun Kang
Radiation Oncology Journal.2013; 31(4): 185. CrossRef

5,741 View
32 Download
1 Crossref

Preliminary Results of Paclitaxel, Cisplatin and Concurrent High-Dose Radiation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Sang wook Lee, Eun Kyung Choi, Suk Joong Oh, Cheol Won Suh, Sang We Kim, Jung Shin Lee, Dong Soon Kim, Won Dong Kim, Woo Seong Kim, Sang Do Lee, Jong Hoon Kim, Seung Do Ahn, Kyoung Ju Kim, Young Ju Noh; Cancer Res Treat. 2002;34(5):345-351. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.345

Abstract PDF

PURPOSE
To investigate the feasibility, toxicity and response rate, of concurrent chemoradiation therapy with paclitaxel/cisplatin in stage III locally advanced non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS
Between May 1999 and December 2000, 80 patients with stage III NSCLC were enrolled in a prospective protocol. Radiotherapy was given to a total dose of 70.2 Gy (daily fraction of 1.8 Gy for 5 days), over an 8 week period, on the gross tumor volume, combined with chemotherapy. The concurrent chemotherapy consisted of paclitaxel (40 mg/m2) and 20 mg/m2 cisplatin per week for 8 consecutive weeks. All patients received 3-D conformal radiotherapy using CT-simulated planning. Acute toxicities were evaluated by the RTOG scale. The median follow-up period was 16 months, ranging from 3 to 29 months.
RESULTS
Of the 80 patients, 71 received treatment per protocol, with minor variation of protocol delivery. The median age of the patients was 60 years. Karnofsky Performance status were 100 and 90 in 62 patients, and 80 and 70 in 9, respectively. Weight loss of less than 5% for 6 months was observed in 22 patients. The response to treatment was evaluated from the radiological findings. Complete and partial responses were observed in 8 and 51 patients, respectively. Ultimately, 82% of patients (included complete responses: 8 cases) obtained more than a partial response. Although, radiation induced esophagitis was the most common treatment related toxicity, occurring in 44 patients (69%), severe radiation esophagitis like, grade 3, was observed in only 3 patients, and the most acute toxicities had completely recovered 1 month following treatment. The overall 2-year actuarial and progression free survivals were 56 and 45%, respectively.
CONCLUSION
This combined modality has activity with manageable toxicity and 23 months in mean survival time in patients with stage III NSCLC. A longer follow up will be required to realise the expected higher survival of these results.

Citations

Citations to this article as recorded by

A Phase II Study of Weekly Paclitaxel, Cisplatin and Concurrent Radiation Therapy for Locally-Advanced Unresectable Non-Small Cell Lung Cancer: Early Closure due to Lack of Efficacy
Se Hoon Park, Mi Kyung Kim, Sun Young Kyung, Young-Hee Lim, Chang Hyeok An, Jeong Woong Park, Seong Hwan Jeong, Jae Woong Lee, Kyu Chan Lee, Eun Kyung Cho, Soo Mee Bang, Dong Bok Shin, Jae Hoon Lee
Cancer Research and Treatment.2004; 36(5): 293. CrossRef

4,344 View
18 Download
1 Crossref

5-Fluorouracil and Cisplatin (FP) with Concurrent Radiotherapy for Locally Advanced Head and Neck Cancer: Hyoung Sam Kim, Ki Seok Kim, Sang Seok Bea, Seok Jin Oh, Ki Hyeong Lee, Won Dong Kim, Woo Yoon Park, Seung Taik Kim; Cancer Res Treat. 2002;34(4):296-301. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.296

Abstract PDF

The combination of chemotherapy and radiotherapy is emerging as the new standard modality for the treatment of locally advanced head and neck cancer, due to the inherent functional and cosmetic sequelae associated with its surgical management. Combination chemotherapy with 5-fluorouracil and cisplatin (FP) is one of the most active regimens for the head and neck cancer. Furthermore, both agents are known to act as radiosensitizer. This study was conducted to determine the efficacy, feasibility, and the toxicities of concurrent FP chemotherapy with radiotherapy.
MATERIALS AND METHODS
Patients with histologically proven locally advanced head and neck cancer (T3-4 or node positive) were enrolled in the study. Patients received 5-fluorouracil, 1,000 mg/m2/day, continuously for 4 days, and cisplatin, 75 mg/m2, on day 1. This regimen was given every four weeks. The radiotherapy (45 Gy) was started on day 1 of the first cycle, and administered in 25 fractions. Following a three-week interval, the radiotherapy was resumed on day 1 of the third cycle of chemotherapy, and administered in 15 fractions (27 Gy).
RESULTS
Of the 31 eligible patients included, 28 were able to be evaluated for the tumor response. The response rate for the 28 patients was 93% (16 complete responses, 10 partial responses). Disease free survival for the 16 complete responders was 37 months (median, 1 ~41 months), with a median follow-up time of 31 months. The 1-, 2-, and 3-year survival rates were 82%, 69%, and 63%, respectively. Regarding the feasibility of this treatments, only nineteen patients (61%) received the complete courses of scheduled treatments. The median duration of admission for all patients was 39 days. Grade 3 or 4 stomatitis were observed in 25 patients (83%) and appeared as the dose limiting toxicity of this regimen CONCLUSION: Although FP chemotherapy with concurrent radiotherapy is toxic, it is an effective and relatively feasible treatment for locally advanced head and neck cancer. The majority of patients experienced severe stomatitis, which appeared as the dose limiting toxicity of this regimen.

Citations

Citations to this article as recorded by

Chemotherapy of Head and Neck Cancer
Chang Ki Yeo
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 291. CrossRef

4,977 View
32 Download
1 Crossref

Nausea and Vomiting Induced by Conventional Fractionated Radiotherapy on Abdomen: Won Dong Kim, Woo Yoon Park; J Korean Cancer Assoc. 2000;32(4):757-763.

Abstract PDF: PURPOSE
A retrospective study was intended to assess the incidence, severity, and risk factors of abdominal radiotherapy induced nausea and vomiting and to evaluate the effect of antiemetic drugs like metoclopramide and ondansetron.
MATERIALS AND METHODS
From October 1997 to October 1999, we enrolled 48 patients who received conventional fractionated radiotherapy on abdomen. Patients under 18 years old and who received concomittant chemotherapy were excluded. Evaluation was carried out on the basis of daily check of the intensity of nausea and any episode of vomiting and retching.
RESULTS
Nausea and vomiting occurred in 65% and 25% of patients, respectively. On multivariate analysis, previous experience with chemotherapy was the only significant patients-related risk factor. The irradiated site and field size were also significant in terms of radiotherapy-related risk factors. Nausea and vomiting were markedly diminished in the group given ondansetron.
CONCLUSION
Our study offered useful data on general picture of radiation induced nausea and vomiting in patients given conventional fractionated radiotherapy on abdomen. For the patients with risk factors, prophylactic antiemetic drug prescription may be mandatory to enhance compliance with radiotherapy and ondansetron is more effective than metoclopramide for controlling nausea and vomiting.

2,163 View
17 Download

The Effect of Pentoxifylline on Rat Spinal Cord Damage to Fractionated Irradiation: Won Dong Kim; J Korean Cancer Assoc. 1998;30(1):178-187.

Abstract PDF: No abstract available.

2,042 View
12 Download

Palliative Radiotherapy for Painful Bone Metastases: Won Dong Kim, Woo Yoon Park; J Korean Cancer Assoc. 1997;29(2):250-256.

Abstract PDF: No abstract available

2,212 View
12 Download

Radiotheraphy of Chondrosarcoma of Bone - A review of 12 cases -: Charn Il Park, Won Dong Kim; J Korean Cancer Assoc. 1994;26(4):637-642.

Abstract PDF: Twelve patients with chondrosarcoma of bone who were treated with radiotherapy at the Seoul National University Hospital between 1979 and 1992 were reviewed. Of the 12 patients, 9 patients were classified with grade I or II chondrosarcoma and 3 patients with mesenchymal or dedifferentiated chondrosarcoma. 3 patients received radiotherapy alone and 9 patients received surgery and postoperative radiotherapy. Tumor doses ranged from 54 Gy to 70 Gy. With a median follow-up of 30 months, three patients died: two with uncontrolled local disease and one with distant metastasis. The remaining 9 patients(75%, 9/12) showed the long-term survival after radiotherapy, which suggests that radiotherapy may be contributed to improve the local control or cure rate in the management of chondrasarcoma of the bone.

2,331 View
13 Download

Radiation Therapy of Carcinoma of the Cervical Stump: Seung Jae Huh, Won Dong Kim, Yong Chan Ahn, Sung Whan Ha, Il Han Kim, Charn Il Park; J Korean Cancer Assoc. 1995;27(6):986-990.

Abstract PDF: We have reviewed 19 cases of cervical stump cancer treated at the Seoul National and Soonchunhyang University Hospital from 1983 to 1993. Patients were treated with external beam radiation and/or intracavitary radiation. Median follow up period is 39 months. The absolute disease free, and overall survival rate for all patients are 51% and 70%, respectively. Six pelvic failures and two distant metastasis were observed. Recurrences were more common in external radiotherapy only or external radiotherapy plus colpostat application group than in the external radiotherapy plus tandem and colpostat treatment group. The grade 2 complication rate was 21%(4/l9) but there were no life threatening complications. Radiation therapy is effective for the treatment of cervical stump cancer.

3,130 View
16 Download

Search